- Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies
This study is looking at a new combination of treatments, including a medicine called Keytruda, for people with blood cancers. Doctors want to see how safe this new combination is and if it helps to treat these cancers. It's an early-stage study to learn more about the treatment.
For: Hematologic malignanciesItaly · Germany · Greece - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)
This study looks at new drug combinations, including KEYTRUDA, for people with advanced lung cancer. Researchers want to see how well these combinations shrink cancer (response rate) and whether they are safe.
For: Stage IV non-small cell lung cancerItaly · Spain · Poland